AtaiBeckley Inc. (ATAI)Healthcare | Biotechnology | New York, United States | NasdaqGM
5.67 USD
+0.70
(14.085%)
⇧
(July 14, 2026, 4 p.m.
EDT)
After hours: 5.75 +0.08 (1.411%) ⇧ (July 14, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:24 a.m. EDT
The investment case for AtaiBeckley is currently broken by a catastrophic failure in its core business metrics. Despite a recent 79% price rebound, the company is hemorrhaging cash with negative free cash flow of -$55 million and operating cash flow of -$106 million. Fundamentally, the business is deteriorating rapidly, with revenue contracting by nearly 39% year-over-year and operating margins collapsing to -32%. The balance sheet is fragile, carrying significant debt against minimal equity, resulting in a negative return on equity of nearly -380%. While the stock trades at a low absolute price, the valuation multiples are absurdly inflated given the lack of earnings or positive cash generation, suggesting the market is pricing in a miraculous turnaround that the current data does not support. The heavy put activity confirms that sophisticated traders see this as a high-risk speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| MSTL_90 ✓ | 0.093744 |
| AutoARIMA | 0.098685 |
| MSTL_45 | 0.115422 |
| MSTL_45_90 | 0.116867 |
| MSTL | 0.120279 |
| AutoETS | 0.126227 |
| AutoTheta | 0.140103 |
Forecast horizon: 60 days | Selected: MSTL_90
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 2.21 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.107 |
| Excess Kurtosis | -1.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.585 |
| Revenue per Share | 0.013 |
| Market Cap | 2,087,505,152 |
| Forward P/E | -12.58 |
| Beta | 1.57 |
| Previous Name | Atai Life Sciences N.V. |
| Website | https://www.ataibeckley.com |
As of July 11, 2026, 3:24 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes 3.0 and 4.0) relative to calls. The implied volatility skew is inverted, with deep OTM puts trading at significantly higher premiums than OTM calls, indicating a market consensus expecting further volatility and potential price declines rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.8754717 |
| Address1 | 250 West 34th Street |
| All Time High | 22.91 |
| All Time Low | 1.025 |
| Ask | 6.37 |
| Ask Size | 2 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 9,118,880 |
| Average Daily Volume3 Month | 7,773,686 |
| Average Volume | 7,773,686 |
| Average Volume10Days | 9,118,880 |
| Beta | 1.571 |
| Bid | 4.07 |
| Bid Size | 2 |
| Book Value | 0.543 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.67 |
| Current Ratio | 10.017 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 5.77 |
| Day Low | 4.97 |
| Debt To Equity | 2.585 |
| Display Name | AtaiBeckley |
| Earnings Timestamp | 1,778,589,000 |
| Earnings Timestamp End | 1,786,624,200 |
| Earnings Timestamp Start | 1,786,624,200 |
| Ebitda | -121,896,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -15.275 |
| Enterprise To Revenue | 533.822 |
| Enterprise Value | 1,861,972,096 |
| Eps Current Year | -0.44001 |
| Eps Forward | -0.45076 |
| Eps Trailing Twelve Months | -3.24 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.3839 |
| Fifty Day Average Change | 1.2860999 |
| Fifty Day Average Change Percent | 0.29336888 |
| Fifty Two Week Change Percent | 87.54717 |
| Fifty Two Week High | 6.75 |
| Fifty Two Week High Change | -1.0799999 |
| Fifty Two Week High Change Percent | -0.15999998 |
| Fifty Two Week Low | 2.58 |
| Fifty Two Week Low Change | 3.0900002 |
| Fifty Two Week Low Change Percent | 1.1976745 |
| Fifty Two Week Range | 2.58 - 6.75 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,624,023,000,000 |
| Float Shares | 303,811,139 |
| Forward Eps | -0.45076 |
| Forward P E | -12.578755 |
| Free Cashflow | -55,528,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 99 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -54,607,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.023510002 |
| Held Percent Institutions | 0.43885 |
| Implied Shares Outstanding | 368,166,674 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-06-18 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York. |
| Long Name | AtaiBeckley Inc. |
| Market | us_market |
| Market Cap | 2,087,505,152 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_710359021 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-14 |
| Net Income To Common | -663,398,016 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,829,788,369 |
| Number Of Analyst Opinions | 12 |
| Open | 4.97 |
| Operating Cashflow | -105,924,000 |
| Operating Margins | -32.39099 |
| Payout Ratio | 0.0 |
| Phone | 332 282 0507 |
| Post Market Change | 0.07999992 |
| Post Market Change Percent | 1.4109334 |
| Post Market Price | 5.75 |
| Post Market Time | 1,784,073,585 |
| Prev Name | Atai Life Sciences N.V. |
| Previous Close | 4.9700003 |
| Price Eps Current Year | -12.88607 |
| Price Hint | 2 |
| Price To Book | 10.441989 |
| Price To Sales Trailing12 Months | 598.482 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.806 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.14286 |
| Region | US |
| Regular Market Change | 0.6999998 |
| Regular Market Change Percent | 14.084503 |
| Regular Market Day High | 5.77 |
| Regular Market Day Low | 4.97 |
| Regular Market Day Range | 4.97 - 5.77 |
| Regular Market Open | 4.97 |
| Regular Market Previous Close | 4.9700003 |
| Regular Market Price | 5.67 |
| Regular Market Time | 1,784,059,201 |
| Regular Market Volume | 11,875,227 |
| Return On Assets | -0.33338 |
| Return On Equity | -3.77996 |
| Revenue Growth | -0.387 |
| Revenue Per Share | 0.013 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 368,166,674 |
| Shares Percent Shares Out | 0.082200006 |
| Shares Short | 30,262,372 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 21,794,369 |
| Short Name | AtaiBeckley Inc. |
| Short Percent Of Float | 0.0971 |
| Short Ratio | 3.38 |
| Source Interval | 15 |
| State | NY |
| Symbol | ATAI |
| Target High Price | 25.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 14.16667 |
| Target Median Price | 14.5 |
| Total Cash | 230,767,008 |
| Total Cash Per Share | 0.627 |
| Total Debt | 5,138,000 |
| Total Revenue | 3,488,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.24 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.30085 |
| Two Hundred Day Average Change | 1.3691502 |
| Two Hundred Day Average Change Percent | 0.3183441 |
| Type Disp | Equity |
| Volume | 11,875,227 |
| Website | https://www.ataibeckley.com |
| Zip | 10,119 |